Early-phase clinical trials of agents targeting single points along the IGFR/PI3K/Akt/mTOR pathway reported only mild to moderate adverse events, including hyperglycemia, fatigue, skin rashes and gastrointestinal toxicities [29]. This evidence concerns the gene MTOR and Hyperglycemia.